Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. (Q53591340)
Jump to navigation
Jump to search
scientific article published in September 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. |
scientific article published in September 2006 |
Statements
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. (English)
1 reference
Christopher W Ryan
1 reference
Dezheng Huo
1 reference
Laurence M Demers
1 reference
Tomasz M Beer
1 reference
Leo V Lacerna
1 reference
1 September 2006
1 reference
176
1 reference
3
1 reference
972-8; discussion 978
1 reference
Identifiers
1 reference